Back to search

Peptide record

TPDB91902

Aurein 3.1 Antibacterial Anticancer Antifungal Antiparasitic standard

17 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB91902

Peptide_Name

Aurein 3.1

Activity

Antibacterial Anticancer Antifungal Antiparasitic

Activity_category_statistics

Anti-infective peptides Cancer-related peptides

Database_Source

AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab AFP-GFuse Antifungipept CAFPdb

Sequence_Type

standard

Has_Modification No

Description A 17-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

GLFDIVKKIAGHIAGSI-NH2

FASTA

>TPDB91902|Antibacterial;Anticancer;Antifungal;Antiparasitic|length=17
GLFDIVKKIAGHIAGSI-NH2

Formula C81H135N21O21

Absent Amino Acids RNCEQMPTWY

Common Amino Acids I

Mass 1739.09

PI 9.88

Basic Residues 3

Acidic Residues 1

Hydrophobic Residues 9

Net Charge +1

Boman Index 1.13

Hydrophobicity 0.935

Aliphatic Index 143.53

Half Life

Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 1

number

Amino Acid Distribution

A: 2 R: 0 N: 0 D: 1 C: 0 E: 0 Q: 0 G: 3 H: 1 I: 4 L: 1 K: 2 M: 0 F: 1 P: 0 S: 1 T: 0 W: 0 Y: 0 V: 1

Length

Formula

C81H135N21O21

Mass

1739.09

9.88

Net Charge

Boman Index

1.13

Hydrophobicity

0.935

C_terminal_Modification

Amidation

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial

Origin

Southern bell frog

Evidence 1 Activity

Activity

Activity Endpoint LC50

Activity Raw

LC50=10-100 µM

Detail Source Activity Anticancer

Activity Measurement 10-100 µM

Target

Cancer Type Breast Cancer

Cell Line Breast tumor cellline

Tissue Affected Breast

Assay & Model

Assay Not Available

Testing Time Not Available

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2000

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint LC50

Activity Raw

LC50 = 10 µM

Detail Source Activity Anticancer

Activity Measurement 10 µM

Target

Cancer Type Leukemia Cancer

Cell Line Leukemia tumor cellline

Tissue Affected Blood

Assay & Model

Assay Not Available

Testing Time Not Available

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2000

Evidence 3 Activity

Activity

Activity Endpoint LC50

Activity Raw

LC50 = 10 µM

Detail Source Activity Anticancer

Activity Measurement 10 µM

Target

Cancer Type Lung Cancer

Cell Line Lung tumor cellline

Tissue Affected Lung

Assay & Model

Assay Not Available

Testing Time Not Available

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2000

Evidence 4 Activity

Activity

Activity Endpoint LC50

Activity Raw

LC50 = 10 µM

Detail Source Activity Anticancer

Activity Measurement 10 µM

Target

Cancer Type Colon Cancer

Cell Line Colon tumor cellline

Tissue Affected Colon

Assay & Model

Assay Not Available

Testing Time Not Available

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2000

Evidence 5 Activity

Activity

Activity Endpoint LC50

Activity Raw

LC50=10-100 µM

Detail Source Activity Anticancer

Activity Measurement 10-100 µM

Target

Cancer Type Brain Tumor

Cell Line Brain tumor cellline

Tissue Affected Brain

Assay & Model

Assay Not Available

Testing Time Not Available

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2000

Evidence 6 Activity

Activity

Activity Endpoint LC50

Activity Raw

LC50=10-100 µM

Detail Source Activity Anticancer

Activity Measurement 10-100 µM

Target

Cancer Type Skin Cancer

Cell Line Skin tumor cellline

Tissue Affected Skin

Assay & Model

Assay Not Available

Testing Time Not Available

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2000

Evidence 7 Activity

Activity

Activity Endpoint LC50

Activity Raw

LC50=10-100 µM

Detail Source Activity Anticancer

Activity Measurement 10-100 µM

Target

Cancer Type Ovarian Cancer

Cell Line Ovary tumor cellline

Tissue Affected Ovary

Assay & Model

Assay Not Available

Testing Time Not Available

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2000

Evidence 8 Activity

Activity

Activity Endpoint LC50

Activity Raw

LC50=10-100 µM

Detail Source Activity Anticancer

Activity Measurement 10-100 µM

Target

Cancer Type Renal Cancer

Cell Line Renal tumor cellline

Tissue Affected Renal

Assay & Model

Assay Not Available

Testing Time Not Available

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2000

Evidence 9 Activity

Activity

Activity Endpoint LC50

Activity Raw

LC50 = 10 µM

Detail Source Activity Anticancer

Activity Measurement 10 µM

Target

Cancer Type Prostate Cancer

Cell Line Prostate tumor cellline

Tissue Affected Prostate

Assay & Model

Assay Not Available

Testing Time Not Available

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2000